Tietueen sitaatit

APA-viite (7. p.)
Julian, C., Machado, R. J. M., Girish, S., Chanu, P., Heinzmann, D., Harbron, C., . . . Chen, Y. (2022). Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy. Wiley.
Chicago-viite (17. p.)
Julian, Cristina, et al. Real‐world Data Prognostic Model of Overall Survival in Patients with Advanced NSCLC Receiving Anti‐PD‐1/PD‐L1 Immune Checkpoint Inhibitors as Second‐line Monotherapy. Wiley, 2022.
MLA-viite (9. p.)
Julian, Cristina, et al. Real‐world Data Prognostic Model of Overall Survival in Patients with Advanced NSCLC Receiving Anti‐PD‐1/PD‐L1 Immune Checkpoint Inhibitors as Second‐line Monotherapy. Wiley, 2022.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.